Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Jean-Francois MartiniElizabeth R PlimackToni K ChoueiriDavid F McDermottIgor PuzanovMayer N FishmanDaniel C ChoUlka VaishampayanBradley RosbrookKathrine C FernandezJamal C TaraziSaby GeorgeMichael B AtkinsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
With combined axitinib/pembrolizumab treatment in patients with aRCC, mostly immune-related biomarkers are associated with better treatment outcomes. This exploratory analysis has identified some candidate biomarkers to consider in future prospective testing.